RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

计划入组 16 人 · 首次发布于 2026 年 7 月 30 日

Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets

首次发布于 2012 年 7 月 6 日

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions

首次发布于 2012 年 7 月 6 日

Romiplostim biosimilar (Intas Pharmaceuticals)

factor VIII nanoparticle (Zoetic Pharmaceuticals)

delta opioid agonists/mu opioid antagonists (Dina Pharmaceuticals)

MILESTONE PHARMACEUTICALS

India

XERIS PHARMACEUTICALS INC

United States

KALA PHARMACEUTICALS INC

United States

Rectify Pharmaceuticals Unveils RTY-406, an Oral Dual ABCB4/BSEP Modulator for Primary Sclerosing Cholangitis

Rectify Pharmaceuticals Reports Promising Preclinical Data for RTY-406 in Primary Sclerosing Cholangitis at EASL 2026

Rectify Pharma's Novel Dual-Targeted PFM Shows Promise for Hepatobiliary Diseases at EASL 2025